# A Study of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids

> **NCT00930163** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 218 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** lebrikizumab (MILR1444A)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00930163
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2010-07
- **Final completion:** 2010-09
- **Target enrollment:** 218 (ACTUAL)
- **Last updated:** 2016-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00930163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00930163, "A Study of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00930163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*